CODX: Co-Diagnostics, Inc. - Summary | Jitta

Co-Diagnostics, Inc.

NASDAQ:CODX

Price
$1.13
Loss Chance
58.0%
1.86JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
731 / 1,127
4,088 / 4,929
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (27)
Recent Business Performance (22)
Financial Strength (56)
Return to Shareholders (24)
Competitive Advantage (29)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 163.28% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
1.86
100.00%
2.06
252.89%
Health Care Equipment
4.92
21.15%
6.52
329.03%
5.37
15.06%
COMPANY DESCRIPTION
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.